Comparison of therapeutic potential of macrophage- or mesenchymal stem cell-derived exosomes in pancreatic cancer: An updated review

doi:10.4252/wjsc.v17.i8.107400

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (17)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=17

Aug 26, 2025 (publication date) through Aug 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Aug 26, 2025; 17(8): 107400
Published online Aug 26, 2025. doi: 10.4252/wjsc.v17.i8.107400

Comparison of therapeutic potential of macrophage- or mesenchymal stem cell-derived exosomes in pancreatic cancer: An updated review

Demet Kacaroglu, Nilgun Gurbuz

Demet Kacaroglu, Department of Medical Biology, Faculty of Medicine, Lokman Hekim University, Ankara 06520, Türkiye

Nilgun Gurbuz, Department of Medical Biology, Faculty of Medicine, Suleyman Demirel University, Isparta 32260, Türkiye

Author contributions: Gurbuz N contributed to the supervision, analysis and/or interpretation of this manuscript; Kacaroglu D contributed to the materials of this manuscript; Kacaroglu D and Gurbuz N contributed to the concept, data collection and/or processing, and writing.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Nilgun Gurbuz, PhD, Professor, Department of Medical Biology, Faculty of Medicine, Suleyman Demirel University, Çünür, Doğu Yerleşkesi, 32200 Merkez/ Isparta, Isparta 32260, Türkiye. nilgungurbuz@sdu.edu.tr

Received: March 24, 2025
Revised: April 27, 2025
Accepted: July 7, 2025
Published online: August 26, 2025
Processing time: 151 Days and 22.7 Hours

Core Tip

Core Tip: Pancreatic cancer has high metastatic potential and low survival rates due to its dense desmoplastic microenvironment, which limits drug delivery. Exosomes, with their low immunogenicity and targeting ability, are promising therapeutic carriers. Mesenchymal stem cell- and macrophage-derived exosomes show potential in pancreatic cancer treatment. This review compares their effects, summarizing in vitro, in vivo, and clinical studies while highlighting their advantages and disadvantages.